At a glance
ClinicalIndex Comparison Record- ✓Projected life expectancy of at least 12 weeks
- ✓c-Met overexpressing NSCLC confirmed by VENTANA MET (SP44) RxDx IHC assay
- ✓Histologically or cytologically documented non-squamous NSCLC, locally advanced or metastatic
- ✓Known EGFR activating mutation status (but actionable EGFR mutations not eligible)
- ✕EGFR activating mutations
- ✕Adenosquamous or neuroendocrine histology, or sarcomatoid features
- ✕Prior c-Met-targeted antibodies or telisotuzumab vedotin
- ✕Prior docetaxel therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating Telisotuzumab Vedotin and Docetaxel for Non Small Cell Lung Cancer. Currently recruiting, targeting 698 participants across 317 sites in 32 countries.
Signals
Detailed Summary
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of Teliso-V or Docetax at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 698 adult participants with c-Met overexpressing NSCLC will be enrolled in the study in approximately 330 sites worldwide. Participants will receive IV telisotuzumab vedotin every 2 weeks or docetaxel every 3 weeks until meeting study drug discontinuation criteria. At the conclusion of the study, participants who continue to demonstrate clinical benefit may be eligible to receive study treatment via an extension of the study, a rollover study, or through another mechanism. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study Details
Timeline
Interventions
Intravenous (IV) Infusion
IV Infusion